Detalhe da pesquisa
1.
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
; 149(3): 192-203, 2024 01 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37632469
2.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36879424
3.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35770629
4.
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.
Cardiovasc Drugs Ther
; 2023 Apr 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37052867
5.
The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
Cardiovasc Drugs Ther
; 37(1): 107-116, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34599698
6.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34922353
7.
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Circulation
; 143(11): 1109-1122, 2021 03 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33438437
8.
Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association.
Circulation
; 141(22): e841-e863, 2020 06 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32349541
9.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Circulation
; 141(20): 1608-1617, 2020 05 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32223446
10.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artigo
Inglês
| MEDLINE | ID: mdl-30403574
11.
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Eur Heart J
; 41(42): 4114-4123, 2020 11 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32820320
12.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Eur Heart J
; 41(44): 4245-4255, 2020 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-33051646
13.
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Eur Heart J
; 41(24): 2248-2258, 2020 06 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31732742
14.
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Circulation
; 140(25): 2054-2062, 2019 12 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31707788
15.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Circulation
; 140(2): 103-112, 2019 07 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31117810
16.
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Circulation
; 140(19): 1578-1589, 2019 11 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31475572
17.
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Eur Heart J
; 40(33): 2801-2809, 2019 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31121022
18.
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs.
Vasc Med
; 23(3): 232-240, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29600737
19.
Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial".
Circulation
; 142(20): e335-e336, 2020 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-33196306
20.
Psychosocial predictors of long-term mortality among women with suspected myocardial ischemia: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
J Behav Med
; 39(4): 687-93, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27017335